ArticleScientific reports2025
Exploring the prognostic role and expression patterns of FAM3A family genes in kidney renal clear cell carcinoma.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Kidney renal clear cell carcinoma (KIRC) is the most common subtype of kidney cancer, characterized by complex molecular alterations. The FAM3 gene family, comprising FAM3A, FAM3B, FAM3C, and FAM3D, has been implicated in various cancers, but their roles in KIRC are not well understood. This study investigated the expression, diagnostic potential, and functional significance of FAM3 family genes in KIRC. This study explores the expression and functional roles of FAM3 family genes in KIRC using in silico and in vitro experiments. We performed RT-qPCR analysis to assess the expression of FAM3A, FAM3B, FAM3C, and FAM3D in KIRC and normal cell lines, revealing significant upregulation of FAM3A and FAM3D and downregulation of FAM3B and FAM3C in cancerous cells. ROC analysis demonstrated that FAM3 genes possess high diagnostic potential. Further validation using TCGA, OncoDB, and Human Protein Atlas (HPA) databases confirmed these expression patterns and their association with cancer progression. Methylation analysis indicated hypomethylation of FAM3A and FAM3D and hypermethylation of FAM3B and FAM3C, correlating with differential gene expression. Survival analysis revealed that high FAM3A expression was linked to poor prognosis, while low FAM3C expression correlated with reduced survival. Functional assays demonstrated that knockdown of FAM3A in 786-O cells reduced proliferation, clonogenicity, and migration, underscoring its potential role in KIRC pathogenesis. Additionally, FAM3 genes exhibited significant correlations with immune cell infiltration, immune inhibitor genes, and drug resistance, suggesting their involvement in modulating the tumor microenvironment. The miRNA-mRNA network analysis identified hsa-mir-19b-3p as a key regulator of FAM3 genes, further implicating these genes in KIRC progression. This comprehensive analysis highlights the potential of FAM3 genes as biomarkers and therapeutic targets in KIRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.